8d agoThe StreetBULLISH 67M&A
Lilly looks beyond obesity with $2.88B autoimmune buyout
The maker of Mounjaro and Zepbound just signed its 13th deal of the year.
Archived explainer. For the current picture see today's LLY page.
Why Is ELI LILLY AND CO (LLY) Stock Moving Today?
By the Top Tier Newswire AI Desk · September 4, 2026 at 3:11 PM ET · reviewed against 8 wire stories
ELI LILLY AND CO (LLY) is drawing unusual attention today. Our newswire has captured 8 stories on LLY across 6 sources in the last 36 hours, with AI sentiment reading bullish (avg 62/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Eli Lilly (LLY) shares are moving lower today, down 1.6% as of 4:15 PM ET, amid a combination of recent insider selling and a broader pullback after a strong 52-week high. The stock opened at $1157.80 but has since fallen to $1140.69, with volume at 0.7 million shares, below its 3-month average. The decline comes after a recent wave of bullish commentary and strategic acquisitions that had pushed the stock to record levels.
What Happened
Eli Lilly’s stock has been underpinned by a string of high-profile deals and strong performance from its weight-loss drugs, including Mounjaro and Zepbound. The company announced its 13th acquisition of the year, a $2.88 billion deal for Merida Biosciences to expand its autoimmune and immunotherapy portfolio. This follows a $60 million Series B financing in Superluminal Medicines, in which Lilly participated, and a $8.6 million milestone payment for Nxera Pharma’s progress in obesity-related treatments. JPMorgan Chase recently raised its stance on LLY, citing accelerating sales of its GLP-1 drugs, while The Motley Fool highlighted the company’s ongoing momentum. Despite these developments, the stock has seen a pullback after hitting a 52-week high of $1292.65.
What The Data Shows
The stock has declined 5.2% over the last eight sessions, from $1206.96 to $1143.66. Insider selling has been notable, with three executives, Patrik Jonsson, Donald Zakrowski, and Anat Hakim, selling shares between August 7 and August 18. Congressional trades also show recent activity, with Rep. Dan Newhouse and Rep. Michael Rulli selling between $1,001 and $15,000 of LLY stock in July. Volume today remains subdued at 0.7 million shares, or 0.2 times the 3-month average, suggesting limited follow-through from buyers. The stock is trading at a P/E of 38.9, with a market cap of $1.03 trillion and a beta of 0.51.
What To Watch
The company has no earnings report scheduled in the near term. Investors will likely monitor the breadth of analyst coverage and any further developments in the company’s acquisition strategy.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
LLY by the numbers
7 sessions: -5.24%Coverage: 8 stories / 6 sourcesAI sentiment: 62/100 (bullish)Mkt cap: $1.03TP/E: 38.952w: $712.05 to $1292.65
The headlines behind the move
9d agoTipRanksBULLISH 67Analyst
Eli Lilly Stock (LLY) Gets a Bullish Note from JPMorgan Chase
JPMorgan Chase ($JPM) is pounding the table on the stock of pharmaceutical giant Eli Lilly ($LLY) as sales of its weight-loss drugs accelerate. Chris Schott, a top ...
9d agoThe Motley FoolBULLISH 73General
Great News for Eli Lilly Stock Investors
There is no end in sight for the company's incredible momentum.
10d agoPR NewswireBEARISH 28General
Superluminal Medicines Announces Oversubscribed $60 Million Series B Financing to Advance Lead Program in Rare Genetic Forms of Obesity into the Clinic
Financing led by BVF Partners, L.P. and includes participation from Deep Track Capital and Perceptive Advisors alongside existing investors RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley, and Gaingels Proceeds will support...
10d agoGlobeNewswireBULLISH 63General
Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress
Tokyo, Japan and Cambridge, UK, 3 September 2026 – Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that Centessa Pharmaceuticals Limited ("Centessa"), a wholly-owned subsidiary of Eli Lilly and...
10d agoYahoo FinanceBULLISH 63M&A
Eli Lilly Just Announced a Major Acquisition. Here's What It Means.
The drug giant added to its immunotherapy portfolio.
10d agoYahoo FinanceBULLISH 73Product/PR
Lilly’s Record Stock Price Is Hiding an Even Bigger Opportunity
Eli Lilly just delivered one of the biggest quarters in Big Pharma history, yet the stock sits well below its 52-week high. A closer look at the pipeline and valuation reveals why the real opportunity may still be ahead.
10d agoYahoo FinanceBULLISH 63M&A
Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity
Eli Lilly's $2.875 billion Merida Biosciences deal expands its immunology pipeline, as strong GLP-1 growth continues while LLY shares trail the broader health care sector.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on LLY: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier LLY move explainers: 2026-09-04 · 2026-09-02 · 2026-08-31